To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biogen is set to receive as much as $250 million in funding to develop a late-stage experimental lupus ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries ...